Phenyl derivatives as cannabinoid receptor 2 agonists

A compound of formula (I)

• wherein
• R1 is cyclopropyl, alkyl or haloazetidinyl;
• R2 is cyclopropylmethoxy, alkoxy, haloalkoxy, halopyridinyl, alkylpyrazolyl or halopyrrolidinyl;
• provided that at least one of R1 and R2 is cyclopropyl or cyclopropylmethoxy;
• R3 is —C(O)—NH—C(R4R5)—R6, —C(O)—R7 or R8;
• R4 and R5 are independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkyl sulfonyl alkyl and alkyloxetanyl;
• or R4 and R5 together with the carbon atom to which they are attached form oxetanyl or dioxothiethanyl;
• R6 is aminocarbonyl, 5-methyl-1,2,4-oxadiazol-3-yl, hydroxyalkyl, thiazolyl, alkoxycarbonyl, carboxy, difluoroazetidinylcarbonyl, 5-amino-1,2,4-oxadiazol-3-yl, alkylaminocarbonyl or aminocarbonylalkyl;
• R7 is (aminocarbonyl)(difluoro)pyrrolidinyl or (aminocarbonyl)azaspiro[2.4]heptyl;
• and
• R8 is 3-alkyl-1,2,4-oxadiazol-5-yl or 5-alkyl-1,2,4-oxadiazol-3-yl;
• or a pharmaceutically acceptable salt or ester thereof.